Compounds > 5f-203
Page last updated: 2024-12-08

5f-203

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID396813
CHEMBL ID286593
SCHEMBL ID3050082
MeSH IDM0474602

Synonyms (38)

Synonym
smr001566028
4-(5-fluorobenzo[d]thiazol-2-yl)-2-methyl aniline
mls002702467 ,
nsc703786
NCI60_037037
nsc-703786
5f-203
2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole
CHEMBL286593
4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylaniline
AKOS009453143
bdbm93929
cid_396813
4-(5-fluoranyl-1,3-benzothiazol-2-yl)-2-methyl-aniline
[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methyl-phenyl]amine
benzenamine, 4-(5-fluoro-2-benzothiazolyl)-2-methyl-
260443-89-8
SCHEMBL3050082
5-fluoro2-(4'-amino-3'-methylphenyl)benzothiazole
IFWLHIIUGSEKKE-UHFFFAOYSA-N
DTXSID80327929
5f203
3j3ghw53e4 ,
nsc 703786
unii-3j3ghw53e4
Z412040712
5-fluoro 203
AS-16459
5f 203
EX-A4819
4-(5-fluorobenzo[d]thiazol-2-yl)-2-methylaniline ,
A899551
4-(5-fluorobenzo(d)thiazol-2-yl)-2-methylaniline
2-(4-amino-3-methylphenyl)-
HY-124421
CS-0086441
EN300-85999
AC-36600

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The biphasic dose-response relationship characteristically shown by the benzothiazole series against sensitive cell lines was exhibited by the 4- and 6-fluoro-benzothiazoles (10b,d) but not by the 5- and 7-fluoro-benzothiazoles (10h,i)."( Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
Bradshaw, TD; Browne, HL; Chua, MS; Hutchinson, I; Stevens, MF; Trapani, V; Westwell, AD, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency3.98110.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency3.16230.100020.879379.4328AID588456
ClpPBacillus subtilisPotency15.84891.995322.673039.8107AID651965
Smad3Homo sapiens (human)Potency0.10000.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency5.83340.00018.4406100.0000AID720579; AID720580
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency3.16230.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency1.03230.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency10.00003.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency14.33940.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Heat shock protein hsp-16.2Caenorhabditis elegansIC50 (µMol)55.030045.400045.400045.4000AID651579
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)18.70007.390021.523843.9000AID624474; AID651563
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MSHDrosophila melanogaster (fruit fly)AC503.80000.20909.578848.6900AID743444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID678009Cell cycle arrest in human COLO205 cells assessed as accumulation at S phase at 16 uM after 24 hrs by FACS analysis (Rvb = 3.56 +/- 0.40%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID145750Growth inhibition against ovarian cancer cell line OVCAR-52001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID678007Cell cycle arrest in human COLO205 cells assessed as accumulation at G1 phase at 16 uM after 24 hrs by FACS analysis (Rvb = 71.02 +/- 1.00%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID259223Antiproliferative activity against human breast cancer cell line MCF72006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID1336779Induction of ROS generation in human A549 cells at 100 nM after 48 hrs by DCFDA staining based flow cytometry (Rvb = 4.4%)2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis and biological evaluation of cis-restricted triazole/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers.
AID93637Growth inhibition against ovarian cancer cell line IGROV12001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID678006Cell cycle arrest in human COLO205 cells assessed as accumulation at G1 phase at 8 uM after 24 hrs by FACS analysis (Rvb = 71.02 +/- 1.00%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID678011Cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase at 16 uM after 24 hrs by FACS analysis (Rvb = 23.09 +/- 1.01%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID1336776Induction of mitochondrial membrane potential loss in human A549 cells assessed as intact mitochondrial membrane at 100 nM after 48 hrs by JC-1 staining based flow cytometry (Rvb = 95.9%)2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis and biological evaluation of cis-restricted triazole/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers.
AID266700Antiproliferative activity against human MDA-MB-468 cell line2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzot
AID144652Mean GI50 values are recorded over the NCI 60-cell panel.2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID259226Antiproliferative activity against human colon cancer cell line HCC29982006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID79808Growth inhibition against colon cancer cell line HCC2998; not tested2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID678010Cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase at 8 uM after 24 hrs by FACS analysis (Rvb = 23.09 +/- 1.01%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID145085Growth inhibition against non-small cell lung cancer cell line NCI-H2662001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID266702Antiproliferative activity against human HT29 cell line2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzot
AID1336775Induction of mitochondrial membrane potential loss in human A549 cells at 100 nM after 48 hrs by JC-1 staining based flow cytometry (Rvb = 3.8%)2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Synthesis and biological evaluation of cis-restricted triazole/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers.
AID266701Antiproliferative activity against human MCF7 cell line2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzot
AID678005Induction of apoptosis in human COLO205 cells assessed as accumulation at G0 phase at 16 uM after 24 hrs by FACS analysis (Rvb = 2.28%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID209978Growth inhibition against breast cancer line T-47-D2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID143181Growth inhibition against non-small cell lung cancer cell line NCI-H4602001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID678008Cell cycle arrest in human COLO205 cells assessed as accumulation at S phase at 8 uM after 24 hrs by FACS analysis (Rvb = 3.56 +/- 0.40%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID678004Induction of apoptosis in human COLO205 cells assessed as accumulation at G0 phase at 8 uM after 24 hrs by FACS analysis (Rvb = 2.28%)2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
AID145615Growth inhibition against ovarian cancer cell line OVCAR-42001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID259225Antiproliferative activity against human colon cancer cell line KM122006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID266703Antiproliferative activity against human HCT116 cell line2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzot
AID209039Growth inhibition against cancer cell line TH-102001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID102445Growth inhibition against breast cancer line MCF-72001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID259224Antiproliferative activity against human breast cancer cell line MDA4682006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (51.61)29.6817
2010's13 (41.94)24.3611
2020's2 (6.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.95 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.0310antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
thiazoles
[no description available]		10.632301,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
vincaleukoblastine
[no description available]		2.1510acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
nsc 674495
NSC 674495: structure in first source		3.8130
aminoflavone
aminoflavone: structure in first source		2.5220
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.1110resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.0310actinomycinmutagen
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.1110stilbene
formononetin
[no description available]		2.03104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
fosbretabulin
[no description available]		2.1510stilbenoid
gw 610
2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole: has antineoplastic activity; structure in first source		3.3160
nsc 710305
Phortress: structure in first source		3.8530
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		03.4270
Cancer of Colon
[description not available]		02.0310
Cancer of Lung
[description not available]		02.0310
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.4270
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0310
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Benign Neoplasms
[description not available]		02.0710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0710
Cancer of Stomach
[description not available]		02.2510
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.2510
Adenocarcinoma Of Kidney
[description not available]		02.1510
Cancer of Kidney
[description not available]		02.1510
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		02.1510
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.1510
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.2110
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.2110
Cancer of Ovary
[description not available]		02.0810
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0510
Colorectal Cancer
[description not available]		02.0610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0610